Volume : 11, Issue : 10, October – 2024
Title:
A SHORT REVIEW ON OBESITY: INTRODUCTION, PATHOPHYSIOLOGY AND TREATMENT
Authors :
P.Seeta* , J.N.Suresh Kumar ,B.Manasa,Ch.China Mastan, D.Jayasree , P.Bi Fathima and K.Hari Naga Himaja
Abstract :
Obesity is a complex multifactorial disease that accumulated excess body fat leads to negative effects on health. Obesity continues to accelerate resulting in an unprecedented epidemic that shows no significant signs of slowing down any time soon. Raised body mass index (BMI) is a risk factor for noncommunicable diseases such as diabetes, cardiovascular diseases, and musculoskeletal disorders, resulting in dramatic decrease of life quality and expectancy. The main cause of obesity is long-term energy imbalance between consumed calories and expended calories. Here, we explore the biological mechanisms of obesity with the aim of providing actionable treatment strategies to achieve a healthy body weight from nature to nurture. This review summarizes the global trends in obesity with a special focus on the pathogenesis of obesity from genetic factors to epigenetic factors, from social environmental factors to microenvironment factors. Against this background, we discuss several possible intervention strategies to minimize BMI.
Keywords: obesity,epidemiology, pathophysiology, genetics, epigenetics, microenvironment
Cite This Article:
Please cite this article in press P.Seeta et al., A Short Review On Obesity: Introduction, Pathophysiology And Treatment.,Indo Am. J. P. Sci, 2024; 11 (10).
Number of Downloads : 10
References:
1. ”Ozempic- semaglutide injection. Solution”. DailyMed .Archived from the original on 5 June 2021. Retrieved 5 June 2021.
2. “Rybelsus- oral semaglutide tablet”. DailyMed. Archived from the original on 5 June 2021. Retrieved 5 June 2021.
3. “Wegovy- semaglutide injection, solution”. DailyMed. 4 June 2021. Archived from the original on 14 December 2021. Retrieved 11 March 2022.
4. Doggrell SA (March 2018). “Semaglutide in type 2 diabetes – is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?” (PDF). Expert Opinion on Drug Metabolism&Toxicology. 14 (3):371377. doi:10.1080/17425255.2018.1441286. PMID 29439603. S2CID 3421553. Archived (PDF) from the original on 5 May 2020. Retrieved 12 December 2019.
5. Goldenberg RM, Steen O (March 2019). “Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes”. Canadian Journal of Diabetes. 43 (2): 136–145. doi:10.1016/j.jcjd.2018.05.008. PMID 30195966.
6. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. (November 2016). “Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes”. The New England Journal of Medicine. 375 (19): 1834–1844. doi:10.1056/NEJMoa1607141. PMID 27633186.
7. Li Y, Hansotia T, Yusta B, Ris F, Halban P, Drucker D (2003). “Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis”. The Journal of Biological Chemistry. 278 (1): 471–478. doi:10.1074/jbc.M209423200. PMID 12409292.
8. Dhillon S (February 2018). “Semaglutide: First Global Approval”. Drugs. 78 (2): 275–284. doi:10.1007/s40265-018-0871-0. PMID 29363040. S2CID 46851453.
9. Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, et al. (September 2017). “Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity”. Diabetes, Obesity &Metabolism. 19 (9):12421251. doi:10.1111/dom.12932. PMC 5573908. PMID 28266779
10. Yan, C.; Zeng, T.; Lee, K.; Nobis, M.; Loh, K.; Gou, L.; Xia, Z.; Gao, Z.; Bensellam, M.; Hughes, W.; et al. Peripheral-specific Y1 receptor antagonism increases thermogenesis and protects against diet-induced obesity. Nat. Commun. 2021, 12, 2622. [CrossRef]
11. American Diabetes Association. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes—2021. Diabetes Care 2021, 44, S34–S39. [CrossRef] [PubMed]
12. Centers of Disease Control and Prevention. National Diabetes Statistics Report, 2020; Department of Health and Human Services: Atlanta, GA, USA, 2020.
13. NCDRiskFactor Collaboration. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: Apooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet 2017, 390, 2627–2642. [CrossRef]
14. Blüher, M. Obesity: Global epidemiology and pathogenesis. Nat. Rev. Endocrinol. 2019, 15, 288–298. [CrossRef].
15. Wadden, T.A.; Butryn, M.L.; Hong, P.S.; Tsai, A.G. Behavioral Treatment of Obesity in Patients Encountered in Primary Care Settings. JAMA 2014, 312, 1779–1791. [CrossRef].
16. Mahaffey, K.W.; Neal, B.; Perkovic, V.; de Zeeuw, D.; Fulcher, G.; Erondu, N.; Shaw, W.; Fabbrini, E.; Sun, T.; Li, Q.; et al. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events. Circulation 2018, 137, 323–334. [CrossRef].
17. Gadde,K.M.; Martin, C.K.; Berthoud, H.-R.; Heymsfield, S.B. Obesity: Pathophysiology and management. J. Am. Coll. Cardiol. 2018, 71, 69–84. [CrossRef].
18. Zinman,B.;Wanner,C.;Lachin, J.M.; Fitchett, D.; Bluhmki, E.; Hantel, S.; Mattheus, M.; Devins, T.; Johansen, O.E.; Woerle, H.J.; et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N. Engl. J. Med. 2015, 373, 2117–2128. [CrossRef]
19. S,Y. Pediatric obesity: Causes, symptoms, prevention and treatment. Exp Ther Med. 2016;11(1):15-20. doi:10.3892/etm.2015.2853
20. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 2002;346(6):393–403. doi:10.1056/NEJMoa012512
21. Tserenpil G, Gebre M, Zergham AS, Sekhon AK, Malik BH. Managements for obstructive sleep apnea in adults: review. Cureus. 2020;12(8):e9905. doi:10.7759/cureus.9905
22. Mohanan S, Tapp H, McWilliams A, Dulin M. Obesity and asthma: pathophysiology and implications for diagnosis and management in primary care. Experimental Biology and Medicine. 2014;239(11):1531–1540. doi:10.1177/1535370214525302